Twenty Years' Experience in Retroperitoneal Lymph Node Dissection for Testicular Cancer in a Tertiary Referral Center

Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Jan 28, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the outcomes of a specific surgery called retroperitoneal lymph node dissection (RPLND) in men with testicular cancer. The goal is to understand how effective this surgery is when used as the main treatment for early-stage testicular cancer or for patients who have leftover cancer after chemotherapy. The trial will look at different surgical methods, including traditional open surgery, laparoscopic (a less invasive method), and robotic-assisted surgery.

To participate in this trial, you need to be a man aged 18 years or older who is undergoing RPLND for testicular cancer, either as a first treatment for early-stage cancer or for leftover cancer after chemotherapy. You should be in good health overall, without serious medical issues that would make surgery risky. If you join the trial, you'll be part of a study that aims to gather information from about 120 patients who have already had this surgery between 2000 and 2020, as well as those who are currently being recruited. This research will help doctors better understand the best ways to treat testicular cancer and improve patient outcomes.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Aged ≥ 18 years
• • RPLND of residual mass after chemotherapy in patient with testicular neoplasm seminomatous or nonseminomatous performed by open, laparoscopic, or robotic technique
• • Primary RPLND for seminomatous or nonseminomatous testicular neoplasm of stage I or IIA-IIB with negative markers performed with open, laparoscopic or robotic technique
• • RPLND performed by open, laparoscopic, or robotic technique for the treatment of tumors seminomatous or nonseminomatous chemiorefractory testicular tumors progressing after I and II line of chemotherapy
• • Acquisition of informed consent
• Exclusion criteria:
• • Patient with comorbidities with contraindication to surgery
• • Hemorrhagic diathesis
• • RETROSPECTIVE PHASE. Patients with the same inclusion and exclusion criteria as in the prospective phase and already undergoing RPLND surgery with open, laparoscopic, or robotic technique from January 2000 to December 2020 in the͛framework of the normal course of care with a minimum follow-up of 12 months. (estimated to include approximately 120 patients).